RICHMOND, British Columbia, Feb. 28, 2012 (GLOBE NEWSWIRE) -- BioCurex Inc. (OTCBB:BOCX) announced today that its wholly owned subsidiary, OncoPet™ Diagnostics, Inc., has executed a definitive agreement for distribution of the OncoPet Sample Collection Kit for canine cancer diagnosis in the United States with Animal Health International, Inc., formerly known as Lextron, Inc. (including TW Medical), which acquired Walco International (including DVM Resources) in 2011. Animal Health International is a premier distributor of animal health products in the United States and Canada with broad coverage in both the companion and production animal markets through a series of close to 500 outside and inside sales personnel.
According to the terms of the agreement, Animal Health International will purchase OncoPet Sample Collection Kits from OncoPet Diagnostics for re-sale to veterinarians through an established network of 280 sales representatives and 180 telemarketing staff.
"It is extremely satisfying to see our OncoPet Sample Collection Kit so well received by the animal health industry," stated Dr. Paul Slowey, President of BioCurex. "Animal Health International is one of the top players in the animal health distribution industry with coverage in hard to reach areas, so with the addition of this distribution agreement, we believe OncoPet will be very well represented throughout the entire veterinary community."
About Animal Health International
Animal Health International, Inc. is a premier companion and production animal health distributor offering animal health products and supplies for cattle, equine, poultry, swine, cats and dogs. For more information, please visit www.animalhealthinternational.com.
About BioCurex, Inc.
BioCurex, Inc. is a biotechnology company that is developing products based on patented and proprietary technology in the area of cancer diagnostics. The technology identifies a universal cancer marker known as RECAF.
RECAF is a molecule that is present on cancer cells but not detected in significant levels on healthy cells or benign tumor cells. It is the receptor for alpha-fetoprotein and is classified as an oncofetal antigen due to its presence on both fetal and malignant tissues. This characteristic makes RECAF a more accurate indicator of cancer than most current tumor markers.
BioCurex is commercializing its technology through licensing arrangements with companies that develop and market diagnostic tests for the large automated clinical laboratory setting, through development and marketing of non-automated clinical laboratory tests, through development of rapid, point-of-care test formats, and through marketing of its OncoPet RECAF test for cancer in companion animals.
For further information on these agreements visit:
For more information about the Company, please visit www.BioCurex.com.
For more information about OncoPet Diagnostics Inc., please visit: www.OncoPetDiagnostics.com.
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements, such as forecasts of future sales, involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.
CONTACT: Investor Relations Contact: DC Consulting (407) 792-3333 firstname.lastname@example.org